This Pharma Giant Lost the Vaccine Race, But Its COVID-19 Journey May Not Be Over

Pharmaceutical giant Merck (NYSE:MRK) has been relatively quiet during the COVID-19 pandemic. We saw a few of its peers, Johnson & Johnson and Pfizer, get their COVID-19 vaccines approved for mass manufacturing and commercial use, with governments from all over the world lining up to buy their jabs. However, Merck isn't out of the race yet; it, too, has COVID-19-related products in the pipeline. The combination of a booming pharmaceutical business and new products to help treat COVID-19 should tempt investors to pick up shares in this blue chip company.